Meet with...Leaders from the National Cancer Institute's SBIR program

Sep 6 2017

The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center is coming back to Cambridge! Program directors Michael Weingarten, Andy Kurtz, and Ashim Subedee will be presenting funding opportunities and other resources for startups in cancer technology. You will also learn about twelve new targeted funding opportunities in cancer detection, diagnosis, and treatment in high priority areas of research for the NCI. Although the trends reflect improvements in cancer treatments and advances in technology have led to better tools for understanding, detecting, and diagnosing cancer, we still have work to do. In 2017, an estimated 1,688,780 new cases of cancer will be diagnosed in the United States. The NCI is poised to reduce the burden of cancer in this country and around the world at an accelerated pace.

Program directors will discuss the exciting new non-dilutive targeted funding opportunities in cancer focused technology development. They will explain the application and review process at the NIH to help small businesses submit stronger applications. Additionally, the presentation will review the I-Corps at NIH program, and other initiatives run by NCI to facilitate the success of SBIR companies.

Following the presentation, selected companies will have the opportunity to meet one-on-one with NCI.

National Cancer Institute Participating Representatives:
Andy Kurtz | Team Leader, NCI SBIR Development Center read bio»
Ashim Subedee | Program Director, NCI SBIR Development Center read bio»
Michael Weingarten | Director, NCI SBIR Development Center read bio»

9:00 AM | Registration Opens
9:30 AM | Presentations and Q&A
      - NIH/NCI SBIR Overview and Initiatives
      - Funding Opportunities including the FY 2018 Contract Solicitations
      - Tips on Submitting Competitive Applications
      - Q & A
11:15 AM | Networking Lunch
12:30 PM | Program Close
12:30-3:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on Thursday, August 31, 2017.

Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must register, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 5th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on Thursday, August 31, 2017.

MIT Koch Institute for Integrative Cancer Research
Auditorium (Room 76-156)
500 Main Street
Cambridge, MA 02142

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Participating Representatives' Biographies:
Andy Kurtz, Ph.D. | Team Leader, NCI SBIR Development Center
Dr. Andrew Kurtz is Program Director and Team Leader in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI), where he manages SBIR/STTR awards primarily in the areas of drug development and molecular diagnostics. Since 2009, he has managed the SBIR Phase IIB Bridge program designed to incentivize partnerships between Federally-funded small businesses and third-party investors, in order to accelerate the commercialization of technologies seeded with SBIR/STTR funding. Dr. Kurtz also plays a key role in managing the NCI SBIR Phase IIB Bridge Award, to support the next stage of development for Federally funded SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics. From 2005-2007, Dr. Kurtz served as a AAAS Science and Technology Policy Fellow at the NCI, during which time he helped to launch The Cancer Genome Atlas (TCGA) Pilot Project and also developed policy recommendations to enhance the NIH SBIR/STTR programs. He also has prior industry experience developing high-throughput bioanalytical assays to support pharmacokinetic studies for the biopharmaceutical sector. Dr. Kurtz received a BS in Chemistry from The University of Texas at Austin and a PhD in Biochemistry and Molecular Biology from The University of Texas Medical Branch (UTMB) at Galveston.

Ashim Subedee, Ph.D. | Program Director, NCI SBIR Development Center
Dr. Ashim Subedee is a Program Director at the National Cancer Institute's Small Business Innovation Research (SBIR) Development Center. Ashim manages SBIR & STTR grants and contracts with a focus on cancer therapeutics and theranostics, radiation therapy, cancer imaging, cancer prevention, and digital health. He provides oversight throughout the award period and mentors small business applicants and awardees in developing their technology goals and commercialization strategy. Additionally, he plays an active role in several center initiatives, including investor initiatives, FRAC and other workshops, targeted funding opportunities, and represents the center on the NCI cancer moonshot blue ribbon panel prevention and early detection implementation team. Prior to joining the SBIR Development Center, Ashim was a Presidential Management Fellow at the NIH. As part of the leadership development fellowship program, Ashim did rotations at multiple offices and divisions within the NCI, the NIH Office of the Director, and the FDA CDER. Ashim received his PhD in Biological and Biomedical Sciences from Harvard University in 2015, where his dissertation work in the laboratory of Dr. Kornelia Polyak was focused on molecular mechanisms of triple negative breast cancer.

Michael Weingarten | Director, NCI SBIR Development Center
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in Bethesda, MD. In this role, Mr. Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $135M in grants and contracts annually. The SBIR & STTR programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Mr. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program – the SBIR Development Center.
Under Mr. Weingarten’s leadership, the NCI SBIR Development Center has launched a range of new initiatives to facilitate the success of small businesses developing cancer-related technologies. Recent initiatives include the launch of the NIH I-Corps™ pilot program in which teams of budding entrepreneurs engage in a hypothesis-driven approach to validate their proposed business models by conducting over 100 interviews with potential customers. Companies adjust their strategies based on direct customer feedback and analyze the information they collect to determine if there is a product/market fit. Other NCI SBIR initiatives introduced under Mr. Weingarten's leadership include the NCI SBIR Investor Forums, the NCI SBIR Phase II Bridge Award, and the workshop titled Federal Resources to Accelerate Commercialization (FRAC). Thus far, NCI SBIR has held three investor forums that in total have facilitated the closing of investment deals with NCI-funded SBIR companies valued at over $300M. The NCI SBIR Phase II Bridge Award, which was launched in 2009, incentivizes partnerships between NIH’s SBIR Phase II awardees and third-party investors and/or strategic partners to help small businesses bridge the funding gap between the end of their SBIR Phase II awards and the next round of financing needed to advance a promising cancer therapy or imaging technology.